“ALLOKINE-ALPHA” MUST STOP DISSEMINATING INFORMATION ABOUT ITS EFFICACY FROM COVID-19

Information about “Allkolin-Alpha” on the  medication web-site emphasized its efficacy in prophylactics and treatment of the new coronavirus infection. However, it is corroborated with neither clinical trials nor details of the Instructions for use

As established by Moscow OFAS, “Brand-Pharma” Ltd. published a letter from “Alvils” Ltd. on allokin.ru, addressed to medical facilities but accessible by any site visitor. The letter highlighted that using “Allkolin-Alpha” to treat mild and moderate-severe COVID-19 allegedly shortens the period of eliminating virus from blood cells and prevents development of life-threatening conditions in most patients. The letter reported about positive results of treatment with “Allkolin-Alpha” to prevent disease prevalence among medical workers.

The list of indications in the instruction for use of the medicine, however, does not mention COVID-19. Furthermore, the letter of “Alvils” Ltd. published on allokin.ru, and other sources do not confirm the efficacy of “Allkolin-Alpha” against the new coronavirus infection COVID-19, corroborated with research findings or clinical trials.

At the same time, description of the general  medicine characteristics, its composition and effect upon the human body cannot form the grounds for a firm conclusion about the efficacy of “Allkolin-Alpha” for treating the new coronavirus infection.

According to Moscow OFAS, “Brand-Pharma” Ltd. and “Alvils” Ltd. can mislead the population regarding positive effects of “Allkolin-Alpha” in treating patients with COVID-19 and people who are in contact with COVID-19 patients.

Based on it, the antimonopoly authority issued a warning to the companies to terminate actions that have elements of unfair competition – the companies must stop disseminating unreliable information.

If “Brand-Pharma” Ltd. and “Alvils” Ltd. fail to execute the warning before the deadline, an antimonopoly case shall be opened. If an act of unfair competition is proven, companies shall be held administratively liable and fined up to 500,000 RUB.